Table 2.

Follow up, outcome and further treatment after loss of BCA or relapse in 21 patients with loss of BCA and LTB; A: early loss of BCA < 6 months, B: late loss of BCA≥ 6 months after infusion and C: 5 patients with HTB.

Table 2A
	% Blasts pre-LD	Allo-SCT Pre-CART	First absolute B-cell count and %	Months after infusion Absolute loss BCA	Months after infusion Loss BCA Pennsyl	Months after infusion > 1% B-cell at BM	Clinical decision after loss BCA	Relapse (months after infusion)	Duration of remission since loss of BCA (months)	Intervention after relapse	Allo-SCT post CAR-T (Indication)	Last follow up (months after infusion)
1	0	Yes	12 (1,4)	4	4	3	Wait and see	No	Ongoing		No	Alive (21)
2	0	Yes	85 (2)	3	6	3	Wait and see	No	Ongoing		No	Alive (20)
3	2,5	Yes	16 (7,3)	3	3	6	Wait and see	No	Ongoing		No	Alive (18)
4	0	Yes	9 (0,47)	3	5	3	DLI	Yes (7)	4	Inotuzumab and CAR dual	No	Alive with disease (7)
5	0	No	6 (0,4)	1,5	Not reached	1,5	1° Allo-SCT	No	Ongoing		Yes (early loss BCA)	Alive (27)
6	1,3	No	2 (0,12)	1	Not reached	Not reached	1° Allo-SCT	No	Treatment mortality		Yes (early loss BCA)	Death MRT
7	0	No	1 (0,3)	2	Not reached	Not reached	Rapid progression	Yes (4)	2	Inotuzumab and Allo-SCT	Yes (relapse)	Alive (14)
8	0	No	30 (2)	2	2	Not reached	Rapid progression	Yes (5)	3	Inotuzumab and Allo-SCT	Yes (relapse)	Alive (9)
9	1,6	No	175 (3,8)	2	2	3	1° Allo-SCT	No	Ongoing		Yes (early loss BCA)	Alive (29)
10	3,6	No	112 (na)	5	5	5	1° Allo-SCT	No	Ongoing		Yes (early loss BCA)	Alive (18)
11	0,15	No	36 (6)	5	5	6	1° Allo-SCT	No	Ongoing		Yes (early loss BCA)	Alive (38)
12	0,06	NO	240 (30)	2	2	Non available	Rapid progression	Yes (3)	1	Inotuzumab	Progression	Death (progression)